

CTTI Antibacterial Drug Development Program Update

Pamela Tenaerts, MD, MBA
Executive Director, CTTI

Antibacterial Drug Development Working Group Webinar
August 29, 2013



Antibacterial Drug Development Workstreams

Work stream	Objectives	Deliverables	Anticipated Impact
HABP/VABP Pilot study	Identify barriers and seek solutions for the successful conduct of studies	Recommendations on alternate study design elements to overcome barriers	A trial using the recommendations will show that an innovative approach will work, leading to availability of more ABD products
ID Site Networks	Build a pilot network of sites to conduct HABP/VABP studies	Identifying 30-50 sites with proficiency, interest, and accessibility to the patient population for HABP/VABP trials	Streamlining and accelerating the conduct of HABP/VABP studies
HABP/VABP Patient Focus Group	Assess patients risk, tolerance, and willingness to be treated with drugs approved through non-traditional trials, and to participate in the same	Report/manuscript on patients risk /tolerance. Recommendation on public education of new approaches to drug development and associated risk.	Increasing public awareness about the benefits/risk of new approaches to drug development
Data Collection Simplification	Simplify and reduce the amount of (safety) data collected in HABP/VABP studies	Recommendations on critical data to be collected for a shorter CRF design	Accelerating study conduct, and reducing cost associated with excess data collection